BRPI0417043A - composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição - Google Patents
composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composiçãoInfo
- Publication number
- BRPI0417043A BRPI0417043A BRPI0417043-1A BRPI0417043A BRPI0417043A BR PI0417043 A BRPI0417043 A BR PI0417043A BR PI0417043 A BRPI0417043 A BR PI0417043A BR PI0417043 A BRPI0417043 A BR PI0417043A
- Authority
- BR
- Brazil
- Prior art keywords
- solid dosage
- dosage form
- composition
- pharmaceutical composition
- lercanidipine
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000007909 solid dosage form Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 abstract 3
- 229960004294 lercanidipine Drugs 0.000 abstract 3
- 239000007787 solid Substances 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000007962 solid dispersion Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
"COMPOSIçãO FARMACêUTICA, FORMA DE DOSAGEM SóLIDA, MéTODO DE MANUFATURA DE FORMA DE DOSAGEM SóLIDA, E, USO DA COMPOSIçãO". Uma composição farmacêutica de liberação controlada compreendendo lercanidipina dissolvida ou dispersada em um veículo sólido na temperatura ambiente, formando assim uma dispersão sólida, alcança a liberação retardada de lercanidipina durante um período de tempo prolongado, efeito de alimentação reduzida e biodisponibilidade aumentada comparada com os produtos contendo lercanidipina comercialmente disponíveis.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200301778 | 2003-12-01 | ||
| DKPA200400249 | 2004-02-18 | ||
| US55378704P | 2004-03-16 | 2004-03-16 | |
| PCT/DK2004/000836 WO2005053689A2 (en) | 2003-12-01 | 2004-12-01 | Pharmaceutical compositions comprising lercanidipine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0417043A true BRPI0417043A (pt) | 2007-02-06 |
Family
ID=34657505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0417043-1A BRPI0417043A (pt) | 2003-12-01 | 2004-12-01 | composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070105912A1 (pt) |
| EP (1) | EP1694305B1 (pt) |
| JP (1) | JP2007512265A (pt) |
| KR (1) | KR20060125824A (pt) |
| AU (1) | AU2004294674B2 (pt) |
| BR (1) | BRPI0417043A (pt) |
| CA (1) | CA2547657A1 (pt) |
| DE (1) | DE04801160T1 (pt) |
| EA (1) | EA013426B1 (pt) |
| ES (1) | ES2281313T3 (pt) |
| IL (1) | IL175973A (pt) |
| MX (1) | MXPA06006118A (pt) |
| NO (1) | NO340114B1 (pt) |
| WO (1) | WO2005053689A2 (pt) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005325930B2 (en) * | 2005-01-27 | 2012-01-19 | Alembic Limited | Extended release formulation of Levetiracetam |
| AR053023A1 (es) * | 2005-02-25 | 2007-04-18 | Recordati Ireland Ltd | Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen |
| WO2006119779A2 (en) * | 2005-05-10 | 2006-11-16 | Lifecycle Pharma A/S | A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution |
| NZ575171A (en) * | 2006-08-31 | 2012-04-27 | Aptalis Pharmatech Inc | Drug delivery systems comprising solid solutions of weakly basic drugs |
| US20080175872A1 (en) * | 2006-09-28 | 2008-07-24 | Osmotica Corp. | Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid |
| GB0709541D0 (en) * | 2007-05-17 | 2007-06-27 | Jagotec Ag | Pharmaceutical excipient |
| RU2341262C1 (ru) * | 2007-07-09 | 2008-12-20 | Илья Николаевич Медведев | Способ коррекции ослабления функций стенки сосудов при метаболическом синдроме |
| KR101632079B1 (ko) * | 2007-07-23 | 2016-06-20 | 파마덴 에스.에이. | 디히드로피리딘 칼슘 채널 길항제를 함유하는 약제학적 조성물 및 그것의 제조방법 |
| DE102008022520A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Animal Health Gmbh | Feste Arzneimittelformulierung mit verzögerter Freisetzung |
| AR072477A1 (es) * | 2008-07-11 | 2010-09-01 | Solvay Pharm Bv | Formulacion farmaceutica de eprosartan. uso. |
| US20100209348A1 (en) * | 2009-02-18 | 2010-08-19 | Arondo Pharma, Inc. | Methods for determining liposome bioequivalence |
| WO2012015946A1 (en) * | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Dispersion of rasagiline citrate |
| US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
| US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| UY33772A (es) * | 2010-12-09 | 2012-07-31 | Lg Life Sciences Ltd | Composición farmacéutica que comprende clorhidrato de lercanidipina y valsartán como componentes activos y a un método para la preparacion de la misma. |
| SI2654729T1 (sl) * | 2010-12-24 | 2016-08-31 | Krka, D.D., Novo Mesto | Homogene farmacevtske oralne dozirne oblike, ki obsegajo lerkanidipin in enalapril ali njune farmacevtsko sprejemljive soli skupaj z organsko kislino |
| MX377877B (es) * | 2013-01-14 | 2025-03-11 | Infirst Healthcare Ltd | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. |
| US10588866B2 (en) * | 2014-11-11 | 2020-03-17 | Verdure Sciences | Stable solid lipid particle composition for improved bioavailability of lipophilic compounds for age-related diseases |
| WO2019094688A1 (en) * | 2017-11-10 | 2019-05-16 | Dispersol Technologies, Llc | Improved drug formulations |
| JP6983139B2 (ja) * | 2017-11-27 | 2021-12-17 | 信越化学工業株式会社 | 固形製剤用組成物並びに固形製剤及びその製造方法 |
| AU2019255322A1 (en) * | 2018-04-17 | 2020-11-05 | Poviva Corp. | Lipophilic active agent infused compositions with reduced food effect |
| CN115837012A (zh) * | 2021-01-18 | 2023-03-24 | 广州一品红制药有限公司 | 一种氨氯地平干混悬剂及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20011726A1 (it) * | 2001-08-06 | 2003-02-06 | Recordati Ind Chimica E Farma | Forme polimorfe della lercanidipina cloridrato |
| US20030180355A1 (en) * | 2001-10-16 | 2003-09-25 | Amedeo Leonardi | Combination therapy for hypertension |
-
2004
- 2004-12-01 EP EP04801160.5A patent/EP1694305B1/en not_active Expired - Lifetime
- 2004-12-01 US US10/581,128 patent/US20070105912A1/en not_active Abandoned
- 2004-12-01 DE DE04801160T patent/DE04801160T1/de active Pending
- 2004-12-01 MX MXPA06006118A patent/MXPA06006118A/es not_active Application Discontinuation
- 2004-12-01 AU AU2004294674A patent/AU2004294674B2/en not_active Ceased
- 2004-12-01 KR KR1020067013018A patent/KR20060125824A/ko not_active Withdrawn
- 2004-12-01 JP JP2006540183A patent/JP2007512265A/ja active Pending
- 2004-12-01 ES ES04801160T patent/ES2281313T3/es not_active Expired - Lifetime
- 2004-12-01 WO PCT/DK2004/000836 patent/WO2005053689A2/en not_active Ceased
- 2004-12-01 CA CA002547657A patent/CA2547657A1/en not_active Abandoned
- 2004-12-01 BR BRPI0417043-1A patent/BRPI0417043A/pt not_active IP Right Cessation
- 2004-12-01 EA EA200601075A patent/EA013426B1/ru not_active IP Right Cessation
-
2006
- 2006-05-28 IL IL175973A patent/IL175973A/en active IP Right Grant
- 2006-06-29 NO NO20063036A patent/NO340114B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004294674A1 (en) | 2005-06-16 |
| ES2281313T3 (es) | 2020-07-24 |
| EP1694305A2 (en) | 2006-08-30 |
| NO20063036L (no) | 2006-09-01 |
| EA200601075A1 (ru) | 2006-12-29 |
| EP1694305B1 (en) | 2019-10-16 |
| DE04801160T1 (de) | 2007-08-09 |
| WO2005053689A2 (en) | 2005-06-16 |
| ES2281313T1 (es) | 2007-10-01 |
| EA013426B1 (ru) | 2010-04-30 |
| AU2004294674B2 (en) | 2009-02-26 |
| KR20060125824A (ko) | 2006-12-06 |
| NO340114B1 (no) | 2017-03-13 |
| WO2005053689A3 (en) | 2006-04-27 |
| CA2547657A1 (en) | 2005-06-16 |
| IL175973A0 (en) | 2006-10-05 |
| MXPA06006118A (es) | 2006-08-11 |
| US20070105912A1 (en) | 2007-05-10 |
| JP2007512265A (ja) | 2007-05-17 |
| IL175973A (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE386508T1 (de) | Feste orale dosierungsform enthaltend einen resorptionsverstärker | |
| AU2002218167A1 (en) | N-phenyl-2-pyrimidine-amine derivatives | |
| EP1539122A4 (en) | PHARMACEUTICAL AQUEOUS 2,6-DIISOPROPYLPHENOL COMPOSITIONS | |
| IL168266A (en) | Nucleoside derivatives, processes for their preparation. pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments | |
| EE200300033A (et) | Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon | |
| EA200601075A1 (ru) | Фармацевтические композиции, содержащие лерканидипин | |
| JP2004532810A5 (pt) | ||
| JP2004529078A5 (pt) | ||
| CY1110558T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου | |
| NO20011721D0 (no) | N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor | |
| ATE302616T1 (de) | Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe | |
| BR0206164A (pt) | Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida | |
| WO2005000232A3 (en) | Six membered amino-amide derivatives as angiogenesis inhibitors | |
| BRPI0513455A (pt) | formulação para mascaramento de sabor compreendendo o fármaco em uma forma de dissolução retardada e/ou ciclodextrina em uma forma de dissolução melhorada | |
| AR025052A1 (es) | Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos. | |
| BR0015256A (pt) | Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano | |
| BR0313220A (pt) | Pelìcula de revestimento para comprimidos e cápsulas | |
| CY1110913T1 (el) | Παραγωγα 2-πυρρολιδιν-2-υλο-[1,3,4]-οξαδιαζολης και η χρησιμοποιηση τους σαν αντικαταθλιπτικα | |
| NO20045385L (no) | Farmasoytisk preparat inneholdende okskarbazepin med kontrollert frigivelse av aktivt stoff | |
| DE69923336D1 (de) | Oral anzuwendende buprenorphinhaltige arzneimittel | |
| BR9916575A (pt) | Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa | |
| NO20043792L (no) | New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine | |
| ATE286894T1 (de) | 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen | |
| CY1112057T1 (el) | Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι | |
| BRPI0418726A (pt) | naftalenossulfonato de clopidogrel cristalino ou hidrato do mesmo, método para sua preparação e composição farmacêutica contendo o mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A E 7A ANUIDADE(S) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |